Browsing by author "O'Leary, Benjamin"
Now showing items 1-15 of 15
-
Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
O'Leary, B; Cutts, RJ; Huang, X; Hrebien, S; Liu, Y; et al. (OXFORD UNIV PRESS INC, 2021-03-01)BACKGROUND: There are no established molecular biomarkers for patients with breast cancer receiving combination endocrine and CDK4/6 inhibitor (CDK4/6i). We aimed to determine whether genomic markers in circulating tumor ... -
Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer.
Allin, DM; Shaikh, R; Carter, P; Thway, K; Sharabiani, MTA; et al. (ELSEVIER SCI LTD, 2018-11-01)BACKGROUND: Conventional biomarkers in thyroid cancer are not disease specific and fluctuate in advanced disease, making interpretation difficult. Circulating tumour DNA (ctDNA) has been shown to be a useful biomarker in ... -
Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis.
O'Leary, B; Hrebien, S; Beaney, M; Fribbens, C; Garcia-Murillas, I; et al. (AMER ASSOC CLINICAL CHEMISTRY, 2019-11-01)BACKGROUND: Circulating tumor DNA (ctDNA) assays are increasingly used for clinical decision-making, but it is unknown how well different assays agree. We aimed to assess the agreement in ctDNA mutation calling between ... -
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.
O'Leary, B; Hrebien, S; Morden, JP; Beaney, M; Fribbens, C; et al. (NATURE PORTFOLIO, 2018-03-01)CDK4/6 inhibition substantially improves progression-free survival (PFS) for women with advanced estrogen receptor-positive breast cancer, although there are no predictive biomarkers. Early changes in circulating tumor DNA ... -
ESR1 mutations in metastatic lobular breast cancer patients.
Desmedt, C; Pingitore, J; Rothé, F; Marchio, C; Clatot, F; et al. (NATURE PORTFOLIO, 2019-02-22)Invasive lobular breast cancer (ILC) represents the second most common histology of breast cancer after invasive ductal breast cancer (IDC), accounts for up to 15% of all invasive cases and generally express the estrogen ... -
Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.
Pearson, A; Proszek, P; Pascual, J; Fribbens, C; Shamsher, MK; et al. (AMER ASSOC CANCER RESEARCH, 2020-02-01)PURPOSE: Advanced breast cancer (ABC) has not been subjected to the same degree of molecular scrutiny as early primary cancer. Breast cancer evolves with time and under the selective pressure of treatment, with the potential ... -
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.
Cristofanilli, M; Rugo, HS; Im, S-A; Slamon, DJ; Harbeck, N; et al. (AMER ASSOC CANCER RESEARCH, 2022-08-15)PURPOSE: To conduct an updated exploratory analysis of overall survival (OS) with a longer median follow-up of 73.3 months and evaluate the prognostic value of molecular analysis by circulating tumor DNA (ctDNA). PATIENTS ... -
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Fribbens, C; O'Leary, B; Kilburn, L; Hrebien, S; Garcia-Murillas, I; et al. (2016-09)Purpose ESR1 mutations are selected by prior aromatase inhibitor (AI) therapy in advanced breast cancer. We assessed the impact of ESR1 mutations on sensitivity to standard therapies in two phase III randomized trials that ... -
Reproducibility of Digital PCR Assays for Circulating Tumor DNA Analysis in Advanced Breast Cancer.
Hrebien, S; O'Leary, B; Beaney, M; Schiavon, G; Fribbens, C; et al. (PUBLIC LIBRARY SCIENCE, 2016-10-19)Circulating tumor DNA (ctDNA) analysis has the potential to allow non-invasive analysis of tumor mutations in advanced cancer. In this study we assessed the reproducibility of digital PCR (dPCR) assays of circulating tumor ... -
Science in Focus: Circulating Tumour DNA as a Liquid Biopsy.
O'Leary, B; Turner, NC (2016-12) -
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.
O'Leary, B; Cutts, RJ; Liu, Y; Hrebien, S; Huang, X; et al. (AMER ASSOC CANCER RESEARCH, 2018-11-01)CDK4/6 inhibition with endocrine therapy is now a standard of care for advanced estrogen receptor-positive breast cancer. Mechanisms of CDK4/6 inhibitor resistance have been described preclinically, with limited evidence ... -
Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.
Fribbens, C; Garcia Murillas, I; Beaney, M; Hrebien, S; O'Leary, B; et al. (ELSEVIER, 2017-10-04)BACKGROUND: Selection of resistance mutations may play a major role in the development of endocrine resistance. ESR1 mutations are rare in primary breast cancer but have high prevalence in patients treated with aromatase ... -
Treating cancer with selective CDK4/6 inhibitors.
O'Leary, B; Finn, RS; Turner, NC (NATURE PUBLISHING GROUP, 2016-07-01)Uncontrolled cellular proliferation, mediated by dysregulation of the cell-cycle machinery and activation of cyclin-dependent kinases (CDKs) to promote cell-cycle progression, lies at the heart of cancer as a pathological ... -
Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.
Mansukhani, S; Barber, LJ; Kleftogiannis, D; Moorcraft, SY; Davidson, M; et al. (OXFORD UNIV PRESS INC, 2018-08-27)BACKGROUND: Circulating free DNA sequencing (cfDNA-Seq) can portray cancer genome landscapes, but highly sensitive and specific technologies are necessary to accurately detect mutations with often low variant frequencies. ... -
Value of p53 sequencing in the prognostication of head and neck cancer: a systematic review and meta-analysis.
Basyuni, S; Nugent, G; Ferro, A; Barker, E; Reddin, I; et al. (NATURE PORTFOLIO, 2022-12-01)This review aimed to examine the relationship between TP53 mutational status, as determined by genomic sequencing, and survival in squamous cell carcinoma of the head and neck. The databases Medline, Embase, Web of Science ...